马拉维若、拉替拉韦和利匹韦林在男女泌尿生殖道体液中的渗透与抗病毒疗效
这项前瞻性多中心研究纳入54例HIV-1阳性患者,接受含马拉维若、拉替拉韦或利匹韦林方案超过1个月,配对采集血浆与生殖道样本,检测药物总浓度和游离浓度及HIV-RNA。马拉维若和拉替拉韦在男女生殖道渗透比均>0.5,利匹韦林渗透比低但局部病毒学应答良好。
要点
- 马拉维若和拉替拉韦在男女生殖道渗透良好,生殖道/血浆浓度比>0.5。
- 利匹韦林生殖道渗透比低,但局部病毒学应答仍良好。
- 9例血浆HIV-RNA>50 copies/mL,其中2例血浆药物暴露不足。
核心结论
- 马拉维若和拉替拉韦在男女生殖道渗透良好,局部病毒学应答良好;利匹韦林渗透比低但局部应答良好。
研究设计与样本
- 前瞻性多中心研究,纳入54例HIV-1阳性、年龄>18岁、接受含马拉维若和/或拉替拉韦和/或利匹韦林方案>1个月且自述依从性良好的患者。
- 配对采集血浆和生殖道样本,拉替拉韦和马拉维若于给药后12小时、利匹韦林于给药后24小时采集。
- 检测血浆总浓度和游离浓度、精液总浓度和游离浓度、宫颈阴道分泌物总浓度(干斑)及配对血浆和生殖道HIV-RNA。
主要发现
- 马拉维若和拉替拉韦在男女生殖道生殖道体液/血浆浓度比均>0.5。
- 利匹韦林生殖道体液/血浆浓度比低。
- 抗逆转录病毒药物游离分数与历史数据一致。
- 9例患者血浆HIV-RNA>50 copies/mL,其中2/9血浆抗逆转录病毒暴露不足;另2例患者生殖道体液可检测到HIV-RNA。
临床怎么用
- 对于需要兼顾生殖道局部病毒抑制的HIV-1感染者,马拉维若和拉替拉韦方案可能有助于实现生殖道局部病毒学应答。
- 利匹韦林虽生殖道渗透比低,但局部病毒学应答良好,仍可作为方案组成部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sub-optimal penetration of antiretroviral drugs in genital compartments might promote local HIV persistence and increase the risk of HIV transmission. OBJECTIVES: To describe the penetration of maraviroc, raltegravir, raltegravir glucuronide and rilpivirine in seminal plasma and cervico-vaginal secretions (CVS) and to assess local antiretroviral efficacy in HIV-1-positive patients. METHODS: This was a prospective, multicentre study. Inclusion criteria were HIV-1 positive, age >18 years, receiving regimens containing maraviroc and/or raltegravir and/or rilpivirine for >1 month, and good self-reported adherence. Paired blood and genital samples were collected 12 h (raltegravir and maraviroc) or 24 h (rilpivirine) post-dose. These concentrations were determined (UPLC-MS/MS) in blood and seminal plasma (total and unbound) and CVS (total, dried spots) and HIV-RNA was quantified in paired blood and genital samples. RESULTS: Among the 54 enrolled patients, 15 received maraviroc (6 men), 27 received raltegravir (14 men) and 20 received rilpivirine (10 men), corresponding to 54 total and 52 unbound plasma concentrations, 29 total CVS samples and 23 total and 18 unbound seminal plasma samples. Maraviroc and raltegravir displayed a ratio of genital fluids/plasma concentrations >0.5 in both male and female genital tracts. Conversely, rilpivirine displayed a low ratio. Antiretroviral free fractions were consistent with historical data. Nine patients had blood plasma HIV-RNA >50 copies/mL (2/9 had sub-optimal antiretroviral blood plasma exposure) and two other patients had detectable HIV-RNA in genital fluids. CONCLUSIONS: Maraviroc and raltegravir demonstrated good penetration in genital compartments, yielding good local virological response in genital compartments, whereas rilpivirine presented a low penetration profile but good local response.
引用
- Lê MP, Belarbi L, Chaix ML, et al. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. J Antimicrob Chemother. 2017. PMID: 28961979. doi:10.1093/jac/dkx275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。